ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 63 citations in OpenAlex.
- Multiorientation Simultaneous Computation of Back-Projection CT Image Reconstruction Algorithm in Staging Diagnosis of Bladder Cancer.Computational and mathematical methods in medicine · 2022Trial
- Harnessing intracellular bacteria in bladder by intravesical delivery of antibiotics-loaded nanodiamonds to reduce the recurrence of urinary tract infection.Journal of nanobiotechnology · 2025Article
- Unraveling the multifaceted roles of extracellular vesicles in bladder cancer: diagnostic insights and therapeutic opportunities.Frontiers in oncology · 2025Review
- Nanomedicine in Bladder Cancer Therapy.International journal of molecular sciences · 2024Review
- Tannic Acid Impedes the Proliferation of Bladder Cancer Cells by Elevating Mitochondrial Pathways of Apoptosis.Cell biochemistry and biophysics · 2024Article
- A Novel Approach for Bladder Cancer Treatment: Nanoparticles as a Drug Delivery System.International journal of nanomedicine · 2024Review
- Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist.bioRxiv : the preprint server for biology · 2023Article
- Article
- Mechanisms of Xiaozheng decoction for anti-bladder cancer effects via affecting the GSK3β/β-catenin signaling pathways: a network pharmacology-directed experimental investigation.Chinese medicine · 2023Article
- (Nano)platforms in bladder cancer therapy: Challenges and opportunities.Bioengineering & translational medicine · 2023Review
- Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer.Nature communications · 2022Article
- Application of nanotechnology in the diagnosis and treatment of bladder cancer.Journal of nanobiotechnology · 2021Review
- Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer.Drug delivery and translational research · 2021Article
- Quinazoline Derivatives as Potential Therapeutic Agents in Urinary Bladder Cancer Therapy.Frontiers in chemistry · 2021Review
- Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy.Journal of experimental pharmacology · 2021Review
- Co-Delivery of Cisplatin and Gemcitabine via Viscous Nanoemulsion for Potential Synergistic Intravesical Chemotherapy.Pharmaceutics · 2020Article
- Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.Drug delivery and translational research · 2020Review
- Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation.International journal of molecular sciences · 2020Article
- Hyperthermia Improves Solubility of Intravesical Chemotherapeutic Agents.Bladder cancer (Amsterdam, Netherlands) · 2020Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 3 institutions in 2 countries.
Max KatesDepartment of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland. mkates@jhmi.edu.
Abhijit DateDepartment of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, 200 W. Kawili St., Hilo, HI 96720.
Takahiro YoshidaDepartment of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Umara AfzalThe Center for Nanomedicine, Department of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Pranjali KanvindeThe Center for Nanomedicine, Department of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Taarika BabuThe Center for Nanomedicine, Department of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Nikolai A SopkoDepartment of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Hotaka MatsuiDepartment of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Noah M HahnDepartment of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland.
David J McConkeyDepartment of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Alexander BarasDepartment of Biochemistry, PMAS-Arid Agriculture University, Shamsabad, Rawalpindi, Pakistan.
Justin HanesThe Center for Nanomedicine, Department of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Laura EnsignThe Center for Nanomedicine, Department of Ophthalmology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Trinity J BivalacquaDepartment of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Johns Hopkins University · USKennedy Krieger Institute · USUniversity of Hawaii at Hilo · US
Funding
UH Hilo COP A&RP20GM103466 · NIGMS · UNIVERSITY OF HAWAII AT MANOA · PI HELEN C TURNER · 2012 to 2026
$60.3MThe Role of gp120 on Cardiovascular Disease in People Living with HIVU54MD007601 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI Benjamin C. Fogelgren · 2017 to 2026
$59.5MWilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Ji Yi · 1985 to 2026
$22.1MVector CoreP01HL051811 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI GUGGINO, WILLIAM B. · 1993 to 2013
$20.2MNEI NIH HHS P30 EY001765NHLBI NIH HHS P01 HL051811NIGMS NIH HHS P20 GM103466NIMHD NIH HHS U54 MD007601
Abstract
PubMed holds no abstract for this paper.
Indexed as
Administration, IntravesicalAnimalsAntineoplastic AgentsCell Line, TumorCisplatinHumansMiceNanoparticlesPeptidesPolyethylene GlycolsUrinary Bladder NeoplasmsAntineoplastic AgentsCisplatinPeptidespolyaspartatePolyethylene Glycols
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.